# Long-term Efficacy and Safety Study of GV-971

> **NCT05181475** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Green Valley (Shanghai) Pharmaceuticals Co., Ltd.** · enrollment: 800 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Sodium Oligomannate Capsules (GV-971)

## Key facts

- **NCT ID:** NCT05181475
- **Lead sponsor:** Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-07
- **Primary completion:** 2025-01
- **Final completion:** 2025-06
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181475, "Long-term Efficacy and Safety Study of GV-971". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05181475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*